Johnson & Johnson (JNJ) continues to
experience significant activity in their stocks as investors like Antipodes Partners Ltd and AlphaStar Capital Management LLC make new investments while others like Integrity Alliance LLC, Cooke & Bieler LP, and Assetmark Inc adjust their holdings.
Orthopedics business separation is being pursued by J&J, anticipating growth over 5% by 2026. Meanwhile, J&J is facing a surge of lawsuits in the UK concerning
talcum powder cancer risks, one which has recently led to a $966 million verdict. The litigation issues extend to Tylenol manufacturers J&J and Kenvue, who are being sued by Texas for allegedly concealing the drug's autism risks. On the business front, JNJ is reportedly
in discussions to acquire Protagonist Therapeutics, and their Q3 2025 earnings exceeded expectations, demonstrating strong growth in innovation. Furthermore, the company is seeking FDA approval for icotrokinra, a revolutionary treatment for plaque psoriasis. Finally, Johnson & Johnson has been added to Fortune's list of America's Most
Innovative Companies in 2025.
Johnson Johnson JNJ News Analytics from Mon, 31 Mar 2025 07:00:00 GMT to Sat, 01 Nov 2025 11:59:45 GMT -
Rating 3
- Innovation 5
- Information 6
- Rumor 2
